Yuhan Corporation
Korea's oldest major pharma firm, now living off royalties from a lung cancer drug licensed to J&J.
On the record
Checkpoint: Median overall survival data readout for Rybrevant plus Lazcluze versus Tagrisso at ASCO or ESMO
The call
Yuhan's record profit rides on one licensed drug's royalty stream, with a single 2026 survival data readout able to lock in or stall that income.
Yuhan is a 100-year-old Korean pharmaceutical company that makes and sells its own medicines, plus earns royalties when it licenses drugs to other companies like Johnson & Johnson. Right now, about 10 percent of its profit comes from a single cancer drug called Lazcluze (made by J&J) that is selling much faster than AstraZeneca's older competitor Tagrisso. The tricky part is that Yuhan depends heavily on this one deal: if the planned trial results in late 2026 show Lazcluze is not as good as hoped, or if J&J decides to shift focus elsewhere, the royalty payments could stop growing or shrink. What could change everything is if Yuhan announces new licensing deals with other drugmakers over the next year, which would prove the company can repeat this money-making formula instead of relying on just one partner.
Why
01
AI pressure: AI drug discovery labs like Insilico Medicine and Isomorphic Labs. AI could speed rivals' cancer drug pipelines someday, but Yuhan's income today comes from one already approved combo, not AI risk. Could AI do the core job? Unlikely.
02
Bigger players: AstraZeneca (Tagrisso/osimertinib). Tagrisso is still the widely used first line EGFR lung cancer drug while Rybrevant plus Lazcluze fights to take its place. Could a giant copy it? No, they are blocked.
03
What protects it. Composition of matter patents, FDA and EMA approvals, and an exclusive J&J licensing deal paying royalties on global Lazcluze sales.
What would change this call
H2 2026 median-overall-survival data for Rybrevant-Lazcluze reported at ASCO or ESMO. Shows whether the combo locks in as standard-of-care over AstraZeneca's Tagrisso or stalls.
Announcement (or absence) of new licensing/co-development deals on Yuhan's five post-Lazcluze pipeline candidates within 12 months. Shows whether Yuhan's royalty model repeats beyond one drug or stays concentrated on Lazcluze.
J&J quarterly earnings reports through 2026-2027 and their effect on Yuhan's stock swings. Shows how dependent Yuhan's valuation remains on a single partner's results.
Announcement (or absence) of new licensing/co-development deals on Yuhan's five post-Lazcluze pipeline candidates within 12 months. Shows whether Yuhan's royalty model repeats beyond one drug or stays concentrated on Lazcluze.
J&J quarterly earnings reports through 2026-2027 and their effect on Yuhan's stock swings. Shows how dependent Yuhan's valuation remains on a single partner's results.
Key numbers
- FY2025 net profit up 235.9% to KRW 185.3 billion
- FY2025 revenue KRW 2.1866 trillion, up 5.7% YoY
- Lazcluze got FDA approval in August 2024
Named risks
- Heavy revenue concentration in a single licensed asset (lazertinib/Lazcluze) royalty stream.
- Dependence on partner J&J for commercialization, timing, and milestone recognition, causing quarterly earnings volatility.
- Pending H2 2026 median overall survival data readout could be neutral or negative versus Tagrisso.
- Uncertain success of five post-Lazcluze pipeline candidates in securing licensing deals within 1-2 years.
- Trails domestic peer Hanmi Pharmaceutical on innovation/R&D-intensity rankings.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| AstraZeneca (Tagrisso) | gaining on | Rybrevant-Lazcluze combo sales up 60.8% YoY in Q2 2026, taking share from Tagrisso in EGFR-mutated NSCLC |
| Hanmi Pharmaceutical | losing to | Nature-cited July 2026 ranking places Hanmi in Innovation Leaders tier, Yuhan in Emerging Innovators tier |
| Hanmi Pharmaceutical | losing to | Hanmi led on operating profit (KRW 257.7B) among Korea's top-5 pharma firms in 2025 despite Yuhan leading on revenue |
| GC Biopharma, Chong Kun Dang, Daewoong | contesting | Yuhan ranked #1 by revenue among Korea's top-5 traditional pharma firms in 2025, per 2026-02-19 report |
Questions people ask
- Is Yuhan Corporation profitable in 2026?
- Yes. Yuhan's FY2025 net profit surged 235.9% to KRW 185.3 billion on consolidated revenue of KRW 2.1866 trillion, up 5.7% YoY, driven largely by royalty income from lazertinib (Lazcluze), per a report dated 2026-02-12.
- What is Yuhan's biggest competitor?
- In oncology, Yuhan's licensed drug Lazcluze (with J&J's Rybrevant) is directly displacing AstraZeneca's Tagrisso as first-line EGFR-mutated NSCLC treatment, with combo sales up 60.8% YoY in Q2 2026. Domestically, Hanmi Pharmaceutical is viewed as a stronger innovator, per a 2026-07-01 Nature-cited ranking.
- Could AI replace what Yuhan does?
- Unlikely soon. Yuhan's core moat is a patented, FDA/EMA-approved drug compound (lazertinib) plus an exclusive J&J licensing contract and regulatory approvals across multiple regions, none of which AI tools can replicate or bypass; AI is at most an upstream discovery aid.
- Who owns Yuhan Corporation?
- Yuhan is publicly listed (KRX: 000100) with no controlling family owner; founder Il-han New donated his entire personal stake to form the nonprofit Yuhan Foundation in 1977, and the company has been run by professional management ever since.
- How dependent is Yuhan on a single drug?
- Heavily. Yuhan's 2025 profit surge was driven mainly by royalties from lazertinib (Lazcluze), licensed to J&J, whose Rybrevant-Lazcluze combo hit $734M in global sales in 2025, up from $327M in 2024, per a 2026-01-29 report.
- Did Yuhan miss earnings recently?
- Yes. Yuhan's Q1 2026 results missed consensus, with operating profit of KRW 8.5 billion versus an expected ~KRW 25.6 billion, attributed partly to the timing of milestone payments, according to a 2026-04-20 report.
Timeline
- 2026-07-15Q2 2026 Rybrevant-Lazcluze sales hit $289M, up 60.8% YoY; H1 2026 total $546M, up 70.4%
- 2026-05-28Yuhan discloses five post-Lazcluze pipeline candidates, targets licensing deals within 1-2 years
- 2026-05-13Yuhan receives $30M milestone payment tied to Leclaza's European launch
- 2026-04-20Q1 2026 results miss consensus; operating profit KRW 8.5B vs expected ~25.6B
- 2026-02-12FY2025 results: revenue KRW 2.1866T (+5.7%), net profit up 235.9% to KRW 185.3B
- 2026-01-29J&J reports Rybrevant-Lazcluze 2025 global sales reached $734M, up from $327M in 2024
- 2026-01-21UK NICE issues positive final recommendation for Rybrevant-Lazcluze, reversing negative draft
- 2025-07-17Yuhan stock jumps 20.5% in a single day after J&J earnings beat on Leclaza sales
- 2024-08FDA approves Rybrevant plus Lazcluze combo, Yuhan's first Korean-developed anticancer drug to win FDA approval
- 2018Yuhan out-licenses lazertinib to Johnson & Johnson (Janssen)
Head to head
Revision history
25 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Let's make the best medicine... (2026-06-21)
- Let's make the best medication... (2026-06-21)
- Yuhan Corp. Company Profile & Executives (2025-12-05)
- Yuhan Corporation valuation measures (2026-02-25)
- Yuhan posts record profit on global Lazcluze gains (2026-02-12)
- 000100 Revenue
- Top Five Pharma Firms Near 9 Trillion Won Sales Milestone (2026-02-19)
- Yuhan Corporation Advances Globally on Leclaza Success (2026-06-30)
- J&J's Rybrevant-Lazcluze sales double in 2025 (2026-01-29)
- J&J lifts outlook as Rybrevant, Leclaza sales surge (2026-07-15)
- Yuhan Receives 44.8 Billion Won Milestone from Leclaza Europe Commercialization (2026-05-13)
- Leclaza Global Sales Surge 5-Fold (2026-04-15)